Paramethasone Acetate

Summary

Paramethasone Acetate (CHEMBL1200342) is an approved small molecule (ATC H02AB05).

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: H02AB05
• Chemistry: 434.5 Da · C24H31FO6

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1200342
Name	Paramethasone Acetate
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	443928
ATC	H02AB05
Molecular formula	C24H31FO6
Molecular weight	434.5
InChIKey	HYRKAAMZBDSJFJ-LFDBJOOHSA-N

SMILES: C[C@@H]1C[C@H]2[C@@H]3C[C@@H](C4=CC(=O)C=C[C@@]4([C@H]3[C@H](C[C@@]2([C@]1(C(=O)COC(=O)C)O)C)O)C)F

IUPAC name: [2-[(6S,8S,9S,10R,11S,13S,14S,16R,17R)-6-fluoro-11,17-dihydroxy-10,13,16-trimethyl-3-oxo-7,8,9,11,12,14,15,16-octahydro-6H-cyclopenta[a]phenanthren-17-yl]-2-oxoethyl] acetate

Also known as: Dillar, Haldrone, Parametasona, Paramethasone, Paramethasone acetate, PARAMETHASONE ACETATE, SID144206683, paramethasone acetate

Patent coverage: 1,253 distinct patent families (4,789 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

0 indication records carry no mapped disease name (EFO/MeSH-only); none shown.

Clinical trials

Total trials: 0.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).